Hims & Hers, a telehealth provider, created a Super Bowl ad that criticized the healthcare system and Big Pharma while promoting a cheaper alternative to Ozempic. The ad drew considerable backlash and criticism from the pharmaceutical industry and policymakers. Hims & Hers is attempting to capture a segment of the weight-loss market by offering compounded versions of semaglutide amid shortages of the original products. This move not only raises the company's profile beyond its traditional treatments but also aims for a projected revenue of $100 million in weight-loss drugs by year-end.
In its Super Bowl ad, Hims & Hers attacked 'the system' while promoting a cheaper alternative to Ozempic, positioning itself against Big Pharma's profit motives.
The ad sparked significant backlash, drawing criticism from pharmaceutical companies and politicians alike, reflecting the anti-establishment sentiments of 2025.
As Hims & Hers pushes a compounded version of semaglutide, it aims to capture a weight-loss market poised to reach $100 million in annual revenue.
Despite the controversy, the brand has successfully elevated its image, moving beyond its original focus on erectile dysfunction and hair loss treatments.
Collection
[
|
...
]